Progentos Therapeutics Doses First Participant in Phase 1/2a PRO-1562 Study
Progentos Therapeutics says the first participant has been dosed in its Phase 1/2a study of PRO-1562 for remyelination in multiple sclerosis.
Related stories
Minda Corporation Q2 Revenue Rises 42.6% to Rs 2,189 Crore
Consolidated operating revenue increased year on year from Rs 1,535 crore in the corresponding period last year. EV products accounted for 35% of new orders.
M impact | EQUITY | Nov 03, 2026, 03:33 PM UTC
Intuitive Machines Secures Third NASA Contract in Six Months
The company will provide its spacecraft platform and system integration for NASA’s Falcon-Radar satellite. LUNR shares were up about 7% at the time of writing.
M impact | EQUITY | Nov 03, 2026, 03:32 PM UTC
Remedy Entertainment Reports Q3 Revenue of €39.6 Million, EBIT of €0.6 Million
The company said the results were driven by the launch of CONTROL Resonant, with more than one million copies sold by October 15, 2026. Remedy maintained its full-year revenue and
M impact | EQUITY | Nov 03, 2026, 03:32 PM UTC
Foreign investors buy ₹6,836.81 crore of Indian equities
FIIs recorded their largest single-day net investment of 2026 on Tuesday, November 3, according to exchange data. The inflow surpassed the previous 2026 high of ₹6,688.37 crore on
M impact | EQUITY | Nov 03, 2026, 03:31 PM UTC
Lattice Semiconductor shares surge
Lattice Semiconductor shares surged after its profit outlook exceeded market expectations.
M impact | EQUITY | Nov 03, 2026, 03:31 PM UTC
US session market picture: S&P 500 +0.33%, Nasdaq 100 +0.74%; EUR/USD -0.09%, WTI -0.01%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.33 percent, Nasdaq futures is up 0.74 percent, Dow futures is down 0.53 percent and Russell futures is up 0.69
M impact | EQUITY | Nov 03, 2026, 03:30 PM UTC